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Background: The COVID-19 pandemic introduced new 
challenges in several dimensions in healthcare services. Herein, 
we describe the real-life strategies and therapeutic options 
adopted by dermatologists regarding their patients with 
psoriasis being treated with or with an indication for systemic 
therapy during the first COVID-19 lockdown period in Portugal.
Methods: The study involves a web-based survey on the 
clinical management of systemic therapy for psoriasis 
during the COVID-19 pandemic administered to Portuguese 
dermatologists. The survey consisted of 55 questions (4 open-
ended questions; 51 closed-ended questions), grouped into 6 
sections.
Results: A total of 60 dermatologists voluntarily participated in 
this survey. Nearly 63% of the participants opted for suspending 
biologics during the COVID-19 lockdown period and 23.3% 
increased the time between drug administrations. Eighty 
percent of the participants agreed that biologics did not change 
the probability of acquiring COVID-19 and 58.4% believed 
that these drugs decreased or did not change the severity 
of the disease. Approximately one-third of the participants 
opted not to prescribe a biological agent in patients despite 
clinical indication over the duration of the pandemic. Nearly 
25% of the participants opted for suspending traditional 
immunosuppressant administration. Virtual appointments were 
an option for 93.3% of the participants. 
Conclusion: The COVID-19 pandemic has significantly affected 
the management of patients with psoriasis being treated with 
or with an indication for systemic therapy. Some of the decisions 
made during the first lockdown period were contrary to what 
we know today. These decisions might have had a significant 
impact on patients’ quality of life and on future therapeutic 
success. An adequate interpretation and analysis of the available 
data will be extremely important to an insightful adaptation 
of the clinical practice in future confinement or restrictive 
scenarios.
Keywords: biological agents, COVID-19, dermatology, 
immunosuppression, psoriasis.
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Background
Over the last year, the COVID-19 pandemic has completely 
changed the structure and organization of society in all 
dimensions.1 The infection, caused by SARS-CoV-2, was first 
recognized by its respiratory impairment, although other target 
organ consequences have been subsequently identified.2 Since 
December 2019, when the virus was first identified in China, 
there have been marked advances in knowledge regarding  
the disease and its multiorgan involvement as well as of the 
short-term and long-term management of patients with the 
disease.2 
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The COVID-19 pandemic has reshaped several healthcare 
dimensions. In an attempt to mitigate the spread of the 
virus, healthcare systems have had to adapt their framework 
to decrease the risk of infection in healthcare settings, thus 
limiting in-person visits to the emergent situations. The 
avoidance of healthcare environments in the absence of urgent 
reasons was particularly stressful for patients who are at greater 
risk of developing infections regardless of the infectious agent, 
including individuals with immunodeficiencies or diabetes or 
those on immunosuppressive therapy.3–5 
Several dermatological conditions are treated with systemic 
immunosuppressive/immunomodulatory drugs such as 
cyclosporine, methotrexate or biological agents; psoriasis is 
a typical example.6 Although the impact of these therapeutic 
options on increasing the risk of SARS-CoV-2 infection and 
disease severity remained somewhat uncertain for a long 
period, national and international guidelines on the topic were 
gradually updated based on the clinical experience.7–11 More 
recently, guidelines on the appointment structure (in-person 
versus virtual), prioritization of clinical admissions (urgent 
versus less urgent), and the frequency of visits have also been 
developed.7–12
In Portugal, the first case of COVID-19 was reported on 2 March 
2020, and the first lockdown period started 16 days later, 
lasting until 3 May 2020. During this period, non-face-to-face 
appointments gained special importance as a safe way to 
provide healthcare advice, decreasing the risk of spreading 
the infection.12 This policy was reinforced by the patients’ own 
desire to avoid attending healthcare centres. Faced with all 
these challenges, dermatologists had to reshape their practice, 
with a constant adaptation to balance the best care and patient 
safety.
The present study aims first to describe the attitudes 
and therapeutic options adopted by several Portuguese 
dermatologists – with different expertise in the management 
of psoriasis patients on systemic therapies – regarding the 
management of patients with psoriasis being treated with 
or with an indication for systemic therapy during the first 
COVID-19 lockdown period in Portugal. Secondly, it aims to 
compare the implemented decisions with what is now known 
on the therapeutic options of psoriasis and their impact on the 
COVID-19 pandemic.
Methods 
This is a nationwide cross-sectional study involving a web-
based survey on the clinical management of systemic therapy 
for psoriasis during the COVID-19 pandemic. The web-based 
survey was developed by the Portuguese Group of Psoriasis 
and made available to all members of the Portuguese Society 
of Dermatology and Venereology from 5 November to 26 
November 2020. The participants had to be dermatologists 
who had treated patients with psoriasis with systemic 
therapies. Participation in the study was voluntary. The 
survey consisted of 55 questions (4 open-ended questions; 
51 closed-ended questions), grouped into 6 sections. The 
first section included information regarding participants’ 
experience with patients with psoriasis. The second section 
included information on participants’ attitudes during the first 
COVID-19 lockdown period, whereas the third section included 
questions on their attitudes after the first COVID-19 lockdown 
period. The fourth section included information regarding 
participants’ perception on the impact of immunosuppressive/
immunomodulator therapy during the COVID-19 pandemic. 
The fifth section included information regarding face-to-
face and non-face-to-face consultations during the COVID-19 
pandemic. The last (sixth) section included information 
regarding participants’ awareness of the international and 
national recommendations made available during the 
COVID-19 pandemic.
A descriptive analysis is presented. Categorical variables are 
described using their absolute or relative frequencies, as 
appropriate. Continuous variables are described as mean ± SD.
Results
A total of 60 Portuguese dermatologists who treated 
patients with psoriasis agreed to participate in this study. The 
participants had a mean age of 49.5±12.1 years, with a slight 
female predominance (56.7%). Almost half of the physicians 
had been dermatology consultants for over 20 years and 
65.0% worked in a public healthcare institution. A total of 
59 dermatologists (98.3%) managed patients with psoriasis 
with biological agents and 62.7% of those had more than 
15 patients under this class of drugs. Regarding traditional 
immunosuppressants 43.3% of the participants had more than 
15 patients being treated with cyclosporine or methotrexate. 
Further details are presented in Table 1. 
First COVID-19 lockdown period
Approximately 63% of the dermatologists opted for the 
cessation of the biological agents during the COVID-19 
lockdown period. Half of these (50%) had suspended 
treatment in several patients, whereas the other half (50%) 
suspended treatment only in special cases (not specified). 
Considering the dermatologists who decided to suspend  
the drugs, 52.6% made the decision, with the main reasons 
being (1) disease control (Psoriasis Area Severity Index  
(PASI) of 0); (2) the concomitant presence of other health 
risk factors in their patients for the development of more 
severe COVID-19; or (3) their fear of the possible negative 
impact of therapy during the pandemic. The remaining 
participants (47.4%) mentioned that the decision was based 
on the patient’s choice. The decision to increase the time 
between drug administrations was made by 23.3% of the 
dermatologists. 
The decision of suspending traditional immunosuppressants 
was taken by 26.7% of the participants. From these, 25.0% 
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made their decision based on the patient’s choice, whilst the 
remaining (75.0%) did so on their own initiative. There was a 
greater percentage of dermatologists interrupting cyclosporine 
(81.3%) than methotrexate (62.5%). On the other hand, instead 
of completely suspending the drug, reducing the dosage of 
traditional immunosuppressants was a choice for 23.3% of the 
participants. 
Nearly 37% of the participants opted for a switch of treatment. 
Most of the dermatologists switched to the prescription of a 
different biological agent (not specified), and none switched 
to a traditional immunosuppressant. From the group that 
decided to switch treatment in patients receiving traditional 
immunosuppressants, the majority switched to a biological 
agent. 
Regarding dermatologists’ attitude towards the prescription of 
a biological agent during the lockdown period, 33.3% admitted 
that they opted not to prescribe a biological agent due to the 
pandemic, even in patients with a clinical indication. On the 
other hand, from those who decided to prescribe biologics, 
28.3% did not change their practice during the pandemic and 
38.4% opted to restrict the biological agents to highly selected 
cases (not specified). The COVID-19 pandemic did not influence 
the choice of biological agent prescribed for 40.0% of the 
participants. 
When the prescription of traditional immunosuppressants was 
considered, 40.0% of the dermatologists decided not to do so 
due to the pandemic. Of those who decided to prescribe these 
drugs, the lockdown period did not influence the decision for 
44.4% and 55.6% opted to restrict immunosuppressant agents 
to highly selected cases (not mentioned). When there was a 
choice of drug to prescribe, 44.4% of the dermatologists opted 
for methotrexate.
Virtual consultations were implemented by 93.3% of the 
dermatologists (phone or video call). Further details on  
data from the first COVID-19 lockdown period are provided in 
Table 2. 
Post-COVID-19 lockdown period
After the first COVID-19 lockdown period in Portugal (19 
March to 3 May 2020), 50.0% of the dermatologists decided 
to retain their restrictions on the treatment options, whereas 
Table 1. Participant characteristics.
Characteristics
Total number of participants, n (%) 60 (100.0)
Women, n (%) 34 (56.7)
Men, n (%) 26 (43.3)
Age, mean ±SD 49.5±12.1
Expertise in dermatology, n (%)
Resident 3 (5.0)
Consultant 57 (95.0)
- For less than 10 years 15 (26.3)a
- For 10–20 years 14 (24.6)a
- For more than 20 years 28 (49.1)a
Workplaceb, n (%)
Public healthcare institution 39 (65.0)
Private healthcare institution 39 (65.0)
Solo practice 14 (23.3)
Treating patients with biological agents, n (%) 59 (98.3)
1–5 patients 5 (8.5)c
6–15 patients 17 (28.8)c
>15 patients 37 (62.7)c
Treating patients with traditional immunosuppressants, n (%) 60 (100.0)
1–5 patients 8 (13.4)
6–15 patients 26 (43.3)
>15 patients 26 (43.3)
aProportion compared to the total number of consultants (n=57); bParticipants could 
select more than one option; cProportion compared to the total number of participants 
treating patients with biological agents (n=59). 
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Table 2. Information regarding the first COVID-19 lockdown period.
Decisions
Total number of participants, n (%) 60 (100.0)
Decision to suspend biological agents [Yes], n (%) 38 (63.3)
In which cases?
Several patients 19 (50.0)a
Only in special cases (not specified) 19 (50.0)a
Who made the suggestion?
Physician 20 (52.6)a
Patient 18 (47.4)a
Decision to increase time between biological agent administrations [Yes], n (%) 14 (23.3)
Decision to suspend traditional immunosuppressants [Yes], n (%) 16 (26.7)
Who made the suggestion?
Physician 12 (75.0)
Patient 4 (25.0)
Which agent(s) was(were) suspended?b
Methotrexate 10 (62.5)
Cyclosporine 13 (81.3)
Decision to reduce the dosage of traditional immunosuppressants [Yes], n (%) 14 (23.3)
Decision to switch treatment in patients receiving either biological agents or traditional 
immunosuppressants [Yes], n (%)
22 (36.6)
Decision to initiate a biological agent in patients with that clinical indication [Yes], n (%) 40 (66.7)
In which cases? 
All the patients with that clinical indication 17 (42.5)c
Only in highly selected cases (not specified) 23 (57.5)c
Did the COVID-19 pandemic influence your choice of agent? [Yes], n (%) 24 (60.0)c
Decision to initiate a traditional immunosuppressant in patients with that clinical indication [Yes], n (%) 36 (60.0)
In which cases? 
All the patients with that clinical indication 16 (44.4)d
Only in highly selected cases (not specified) 20 (55.6)d
Any preferred agent? [Yes], n (%) 21 (58.3)d
Methotrexate 16 (76.2)e
Cyclosporine 5 (23.8)e
Decision to implement non-face-to-face consultation [Yes], n (%) 56 (93.3)
aProportion compared to the total number of participants who suspended biological agents (n=38); bParticipants could select 
more than one option; cProportion compared to the total number of participants who decided to initiate treatment with 
biological agents (n=40); dProportion compared to the total number of participants who decided to initiate treatment with 
traditional immunosuppressants (n=36); eProportion compared to the total number of participants who preferred to initiate a 
specific traditional immunosuppressants (n=21).
the other half returned to their usual practice. However, 11.7% 
of the participants in the latter group mentioned that they 
would immediately change their practice in the face of a new 
infectious peak.
When asked about their attitude towards a new lockdown, 
25.0% of the dermatologists answered that they would resume 
the measures that they had implemented in the first wave, 
26.7% answered that they would act as before the emergence 
of the COVID-19 pandemic, and 48.3% answered that they 
would have a restrictive attitude but not as strong as they did 
during the first wave. 
When asked about their attitude on the appointment format, 
93.3% of the dermatologists answered that they decreased the 
number of virtual appointments, gradually resuming face-to-
face appointments. Further details on data from the post-
COVID-19 lockdown period are provided in Table 3.
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positively (46.7%), cyclosporine was the most mentioned drug 
(53.5%), followed by methotrexate (26.7%) and TNF inhibitors 
(11.7%).
Most participants (98.3%) mentioned that they were aware of 
the guidelines and recommendations that emerged during the 
COVID-19 pandemic. Regarding COVID-19 vaccination, 60.0% of 
the dermatologists answered that they will suggest the vaccine 
to all their patients, regardless of ongoing or future treatment. 
All the participants answered that they would suggest the 
vaccine to all patients being treated with or with an indication 
for a biological agent, and 95.0% of the participants would 
suggest it to those already receiving/set-to-start traditional 
immunosuppressants. Further details on the participants’ 
opinion on the impact of the therapeutic options for psoriasis 
during the COVID-19 pandemic are provided in Table 4.
Discussion
Our study provides data on the experience of a group of 
dermatology consultants, with different expertise in the 
management of patients with psoriasis with systemic therapies, 
when managing and treating these patients during the first 
COVID-19 lockdown period. During this period, information and 
guidelines were scarce and most clinical decisions had to be 
made based on peer-to-peer discussions or on the individual’s 
balance between the best treatment care and the perceived 
patient safety. A thoughtful review of the decisions made 
by a heterogeneous group of dermatologists, with different 
expertise in the treatment of psoriasis patients, will help the 
adaptation of a faster response in the scenario of a future 
lockdown period. 
Our results demonstrate that several dermatologists decided to 
suspend biological agents and traditional immunosuppressants, 
probably related to the described association of these drugs 
with the increased risk for upper respiratory tract infections, 
which culminates in an increased risk of worsening psoriasis.4,13 
The proportion of dermatologists that decided to suspend 
Participants’ opinion on the impact of 
therapeutic options for psoriasis during the 
COVID-19 pandemic
Portuguese dermatologists were asked about their opinion 
on the impact of biological agents on the risk of SARS-CoV-2 
infection; 80% of the participants answered that, in their opinion, 
this type of drugs did not change the probability of infection, 
whereas 10.0% defended that these drugs could increase the 
risk of SARS-CoV-2 infection and 1.7% answered that these 
drugs decreased the risk of infection. Regarding the impact 
of biological agents on the clinical evolution and prognosis of 
COVID-19, 23.3% answered that these drugs were responsible 
for an increased risk of severe disease, 16.7% mentioned that 
biological agents could decrease the disease severity, and 41.7% 
answered that biological agents did not change the severity 
of COVID-19. Regarding the preference for a biological agent 
during the COVID-19 pandemic, 38.3% of the dermatologists 
answered that they did not have a preferred agent. From those 
who had a preference, only 1.7% preferred TNF inhibitors, whilst 
the vast majority selected IL-17 and IL-23 inhibitors.
The opinion of Portuguese dermatologists regarding the impact 
of traditional immunosuppressants on the risk of infection by 
SARS-CoV-2 was also addressed; 30.0% answered that they 
believed these drugs to be responsible for an increased risk 
of SARS-CoV-2 infection, none thought that these agents 
could decrease the risk, and 56.7% mentioned that traditional 
immunosuppressants did not have any impact on the risk of 
infection. Regarding the impact of these agents on the evolution 
and prognosis of the disease, 45.0% believed that traditional 
immunosuppressants were responsible for an increase of 
severity of COVID-19, 6.6% mentioned that these agents were 
responsible for a decreased disease severity, and 21.7% referred 
that these drugs did not change the course of the disease.
When the dermatologists were asked if there was, in their 
opinion, an association between a specific agent and the 
increase of COVID-19 severity, from those who answered 
Table 3. Information regarding the post-COVID-19 lockdown period.
Total number of participants 60 (100.0)
Decision to suspend restrictions regarding treatment implemented during the first lockdown [Yes]
Immediately return to the restrictions that were implemented during the first COVID-19 lockdown 
period in the face of a new infectious peak
30 (50.0)
7 (11.7)
Which action will you take regarding a new lockdown? 
Resume the measures implemented during the first lockdown
Act as before the COVID-19 pandemic




Decision to gradually return to the face-to-face consultation format [Yes] 56 (93.3)
All the results were made available in n (%), with n representing the number of cases and the percentage representing the 
proportion compared to the total number of participants.
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Table 4. Data on dermatologists’ opinion on the impact of therapeutic options for psoriasis during the COVID-19 
pandemic.
Opinion
Total number of participants 60 (100.0)
Regarding biological agents and SARS-CoV-2 infection









Do they impact on the evolution/prognosis of the disease caused by the infectious agent?
Increase the severity 14 (23.3)
Decrease the severity 10 (16.7)
No impact on the severity 25 (41.7)
No opinion 11 (18.3)
Do you have any preferred agent to use during the COVID-19 pandemic?
No 23 (38.3)
Yes. Which agents? 37 (61.7)
- TNF inhibitors 1 (1.7)
- Dual IL-12/23 inhibitors 11 (18.3)
- IL-17 inhibitors 36 (60.0)
- IL-23 inhibitors 35 (58.3)
Regarding traditional immunosuppressants and SARS-CoV-2 infection
Do they increase or decrease the risk of infection?
Increase 18 (30.0)
Decrease 0 (0.0)
No impact 34 (56.7)
No opinion 8 (13.3)
Do they impact on the evolution/prognosis of the disease caused by the infectious agent?
Increase the severity 27 (45.0)
Decrease the severity 4 (6.6)
No impact on the severity 13 (21.7)
No opinion 16 (26.7)
Is there an association between any specific therapeutic agent and the increase of  
severity of COVID-19?
No 2 (3.3)
Do not know/not enough data 30 (50.0)
Yes. Which one? 28 (46.7)
Cyclosporine 15 (53.6)
Methotrexate 7 (25.0)
TNF inhibitors 3 (10.7)
Other agents (not specified) 3 (10.7)
Were you aware of the guidelines and recommendations that emerged during the COVID-19 pandemic? 
No 1 (1.7)
Yes. Which ones?a 59 (98.3)
(Continued)
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COVID-19 pandemic, might induce the worsening of psoriasis 
and condition the future response to the various therapeutic 
options to be proposed.19 An inadequate treatment results in 
an incalculable impact on the patients’ quality of life.19 A group 
of Portuguese dermatologists claim that they would have an 
equally restrictive attitude in future lockdowns. It is important 
to reinforce that, from what we know today about the impact of 
the different therapeutic options on SARS-CoV-2 infection, this 
attitude does not seem appropriate and might have negative 
effects in their patients’ quality of life. 
The increase in the number of virtual appointments was a 
solution adopted by clinicians and healthcare administrations 
to ensure the proper and possible support for their patients 
when there was a lack of information about SARS-CoV-2. 
This strategy sought to decrease the risk for the patients but 
also the risk for disseminating the infection at healthcare 
centres.12 However, objective examination and medical 
evaluation are irreplaceable in dermatology and the long-term 
implementation of virtual appointments is unsustainable. 
We now know that the risk of being infected by COVID-19 is 
markedly reduced by ensuring proper hygiene measures, social 
distancing and the use of facemasks.20–22 Additionally, the 
awareness of the entire population for COVID-19-associated 
signs and symptoms and the prevention strategies that have 
been implemented in healthcare facilities will ultimately 
contribute to a gradual resumption of phototherapy and 
face-to-face visits. Lastly, the recent approval of vaccines 
that demonstrated a high safety and efficacy profile was an 
essential milestone in this long path to resume our society to 
the pre-COVID-19 era.23 
Conclusion
Our study summarizes the strategies and clinical decisions of 
several Portuguese dermatology consultants – with different 
Table 4. (Continued)
Opinion
National guidelines and recommendations 57 (95.0)
International guidelines and recommendations 46 (76.7)
Will you suggest the COVID-19 vaccine to all your patients?b 36 (60.0)
Yes 36 (60.0)
No, but at least to those already receiving/set-to-start biological agents 24 (40.0)
No, but at least to those already receiving/set-to-start traditional immunosuppressants 21 (35.0)
No, but at least to those already under/set-to-start phototherapy 2 (3.3)
No, but at least to those already receiving/set-to-start acitretin 2 (3.3)
aParticipants could select more than one option; bParticipants could select more than one option if they did not select the 
answer ‘All patients’. 
All the results were made available in n (%), with n representing the number of cases and the percentage representing the 
proportion compared to the total number of participants.
TNF, tumour necrosis factor.
biological agents in our study is higher than that registered in 
Italy in the PSO-BIO-COVID study – an observational study that 
aimed to evaluate the impact of COVID-19 on the management 
of psoriasis during the pandemic and that was supported by 
the Italian Society of Dermatology14 – which might represent 
a more defensive strategy from Portuguese dermatologists. 
The current and updated knowledge shows that biological 
agents do not seem to increase the risk of infection by SARS-
CoV-2 compared to the risk for rest of the population.2,7,11,15 In 
addition, evidence suggests that patients being treated with 
biological drugs do not develop a more severe spectrum of 
the disease or have a worse prognosis.2,7,11,14,15 Interestingly, 
COVID-19 seems to induce an immune event known as a 
‘cytokine storm’, an inappropriate host-inflammatory  
response that seems to be even more exacerbated in patients  
with more severe disease.10,15 Therefore, several targeted 
therapies – some of them also used in psoriasis, such as 
ixekizumab or adalimumab – have been introduced in clinical 
trials to evaluate their effectiveness in treating patients with 
SARS-CoV-2 infection.15 
Despite the greater concern of Portuguese dermatologists 
regarding TNF inhibitors, current data also seem to indicate 
that patients recently exposed to these biological agents do 
not have a higher risk of hospitalization or mortality associated 
with COVID-19 when compared to the rest of the population.16 
Traditional immunosuppressants were also a point for 
disagreement among Portuguese dermatologists. However, 
recent data seem to indicate that exposure to methotrexate 
or cyclosporine do not increase the risk of hospitalization or 
mortality compared with patients infected with SARS-CoV-2 
without recent exposure to these drugs.16–18 
Several participants decided not to prescribe the appropriate 
therapy in certain situations due to the COVID-19 pandemic. 
Undertreatment, a problem that has been identified in the 
past, discussed for several years and intensified during the 
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were contrary to what is known today about the therapeutic 
options in psoriasis and the COVID-19 pandemic. Our analysis 
highlights and discusses important healthcare practice 
adaptations that will be essential for future lockdown periods.
expertise in the management of patients with psoriasis with 
systemic therapies – on how to manage patients with psoriasis 
on systemic treatments during the first COVID-19 lockdown 
in Portugal. Some of the decisions made during that period 
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